What is Chardan Capital's Forecast for DYN FY2025 Earnings?

Key Points

• Chardan Capital has lowered its FY2025 EPS estimate for Dyne Therapeutics to ($3.47) from ($3.40), maintaining a "Buy" rating with a price target of $38.00.
• Dyne Therapeutics reported quarterly earnings of ($0.97) EPS, which exceeded analyst expectations of ($0.99), recovering slightly from previous estimates.
• Insider trading showed CEO John Cox purchased 100,000 shares at $9.11 each, significantly increasing his stake in the company by over 70%.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Research analysts at Chardan Capital dropped their FY2025 EPS estimates for Dyne Therapeutics in a research note issued to investors on Tuesday, July 29th. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings of ($3.47) per share for the year, down from their prior forecast of ($3.40). Chardan Capital currently has a "Buy" rating and a $38.00 price target on the stock. The consensus estimate for Dyne Therapeutics' current full-year earnings is ($3.44) per share. Chardan Capital also issued estimates for Dyne Therapeutics' FY2026 earnings at ($3.10) EPS.

DYN has been the topic of a number of other reports. HC Wainwright lowered their target price on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Jones Trading assumed coverage on shares of Dyne Therapeutics in a research note on Thursday, June 26th. They set a "buy" rating and a $30.00 price objective for the company. Guggenheim reissued a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, June 18th. JPMorgan Chase & Co. dropped their target price on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating on the stock in a research report on Tuesday, July 15th. Finally, Sanford C. Bernstein started coverage on Dyne Therapeutics in a research note on Tuesday, June 24th. They set a "market perform" rating and a $13.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $36.25.

Dyne Therapeutics Price Performance

NASDAQ:DYN traded up $0.36 during mid-day trading on Friday, reaching $10.61. 1,626,540 shares of the stock were exchanged, compared to its average volume of 2,562,064. The business has a fifty day moving average price of $10.68 and a 200 day moving average price of $11.40. The firm has a market capitalization of $1.51 billion, a PE ratio of -2.75 and a beta of 1.08. Dyne Therapeutics has a 1-year low of $6.36 and a 1-year high of $47.45. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.99) by $0.02.

Insider Activity

In other news, CEO John Cox acquired 100,000 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The stock was acquired at an average cost of $9.11 per share, for a total transaction of $911,000.00. Following the completion of the acquisition, the chief executive officer owned 242,179 shares in the company, valued at $2,206,250.69. This represents a 70.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 14.14% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS acquired a new position in Dyne Therapeutics in the 4th quarter valued at $257,000. Norges Bank acquired a new position in Dyne Therapeutics in the 4th quarter valued at $22,384,000. Pictet Asset Management Holding SA increased its stake in shares of Dyne Therapeutics by 6.2% in the 4th quarter. Pictet Asset Management Holding SA now owns 323,552 shares of the company's stock valued at $7,623,000 after purchasing an additional 18,847 shares during the last quarter. Schroder Investment Management Group increased its stake in shares of Dyne Therapeutics by 63.3% in the 4th quarter. Schroder Investment Management Group now owns 147,002 shares of the company's stock valued at $3,477,000 after purchasing an additional 56,961 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Dyne Therapeutics by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company's stock worth $44,476,000 after acquiring an additional 27,916 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.